Zarxio Wins First Biosimilar Approval, but isn't Considered Interchangeable

Source: Business Wire

Mar 10, 2015

The U.S. FDA has approved Zarxio, the first drug in the U.S. that was developed through the recently established biosimilar regulatory pathway, clearing the way for market competition.

Novartis Sandoz' Zarxio, a similar version of Amgen's reference biologic, Neupogen (filgrastam), was approved last week for all of the same indications as Neupogen. The approval will open the door for other drugmakers to pursue biosimilar versions of Neupogen.

However, pharmacists will not be able to automatically substitute Zarxio for Neupogen, which means physicians will have to specifically prescribe Zarxio for patients. Additionally, while Zarxio will be priced competitively relative to Neupogen, the cost savings between the two drugs in the EU is only a 26% discount -- much less than the discount seen in the traditional, small molecule generic drug market.

According to Seeking Alpha, Amgen and Sandoz will be in federal court on Friday to argue over an injunction sought by Amgen, seeking to block the launch because Sandoz has declined to participate in patent disclosure procedures.

Read the business wire press release

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments